Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1681-1700 of 3,900 trials

Corneal Endothelial Transplantation: NSAIDs vs. Steroids

We are comparing two medication regimens to see if adding NSAIDs helps reduce inflammation and cystoid macular edema after corneal endothelial transplantation. This study is for patients undergoing this specific eye surgery.

Fuchs Dystrophy>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesOphthalmology

Metastatic Colorectal Cancer: Personalized Treatment Study

We are investigating whether tailored therapies based on genetic testing can improve treatment outcomes for patients with metastatic colorectal cancer. This study aims to assess the effectiveness and safety of these new treatment options.

Metastatic Colorectal CancerEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Breast Cancer: Personalized Treatment with Capivasertib

We are studying a new treatment combining capivasertib with letrozole for women with hormone receptor positive breast cancer. This trial aims to see if this approach improves survival compared to standard treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Cardiac Arrest: Amiodarone Treatment Study

We are investigating whether giving amiodarone to critically ill patients after a cardiac arrest can lower the risk of death and serious heart rhythm problems. This study focuses on patients with a shockable rhythm and aims to improve their outcomes.

Out-of-Hospital Cardiac Arrest>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

ARDS Treatment: Recombinant Human Plasma Gelsolin

We are studying whether intravenous recombinant human plasma gelsolin is safe and may help patients with moderate-to-severe ARDS caused by pneumonia or infections. This trial compares it to a placebo alongside standard care.

Acute Respiratory Distress Syndrome (ARDS)≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPulmonology

Metastatic Squamous Non-Small Cell Lung Cancer: Pembrolizumab Study

We are studying the effects of pembrolizumab alone or with MK-2870 in patients with metastatic squamous non-small cell lung cancer. The goal is to see which treatment may improve survival and quality of life.

Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Non-Hodgkin’s Lymphoma: ARV-393 Study

We are evaluating a new treatment called ARV-393 for adults with advanced Non-Hodgkin’s Lymphoma. The goal is to see how well it works and its safety compared to current options.

Advanced Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Oncology

Cerebral Amyloid Angiopathy: ALN-APP Treatment Study

We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.

Cerebral Amyloid Angiopathy1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Sufentanil for Pain Management in Abdominal Surgery

We are studying how the use of sufentanil during non-major abdominal surgery affects long-term pain and recovery. This trial looks at both immediate and chronic pain experiences in patients.

Chronic Postsurgical Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Chronic Lymphocytic Leukemia: Acalabrutinib Treatment Study

We are investigating whether acalabrutinib is safe and effective for adults with chronic lymphocytic leukemia and heart problems. This study compares it to other treatment options available for these patients.

Chronic Lymphocytic Leukaemia with Cardiac Impairment>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyHematology

Systemic Lupus Erythematosus: Rapcabtagene Autoleucel Study

We are studying a new treatment for people with difficult-to-treat kidney disease caused by systemic lupus erythematosus. The goal is to see if it works better than standard care in improving kidney health.

Systemic Lupus Erythematosus with Lupus Nephritis1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrologyRheumatology

Early Breast Cancer: Abemaciclib and Giredestrant Study

We are investigating the safety and effectiveness of two medications for patients with early-stage, hormone-sensitive breast cancer before surgery. The goal is to see if this treatment can help reduce tumor size and improve outcomes.

Early Breast Cancer (ER-positive, HER2-negative)6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Myelodysplastic Syndromes: Ivosidenib vs. Azacitidine

We are studying the effects of a new drug, ivosidenib, in adults with myelodysplastic syndromes who have an IDH1 mutation. The goal is to understand its effectiveness and safety compared to azacitidine.

Myelodysplastic Syndrome (MDS)Hypomethylating Agent Naive Myelodysplastic Syndromes>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Thyroid Eye Disease: Sirolimus vs. Corticosteroids

We are comparing a new treatment called Sirolimus with corticosteroids for people with active thyroid eye disease. The goal is to see if Sirolimus is more effective and has fewer side effects.

Thyroid Eye Disease≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOphthalmology

Long-Term Study of Galapagos CAR T-Cell Therapies

We are evaluating the long-term safety and effectiveness of Galapagos CAR T-cell therapies in patients. This study aims to understand how these treatments work over many years.

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Rheumatoid Arthritis: Proactive Drug Monitoring Study

We are investigating whether proactive monitoring of a TNF inhibitor helps adults with rheumatoid arthritis maintain better disease control without flare-ups compared to standard care.

Rheumatoid Arthritis1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesRheumatology

High-Grade Soft Tissue Sarcoma: Ifosfamide and Doxorubicin Study

We are studying a combination of chemotherapy drugs for patients with localized high-grade soft tissue sarcoma. The goal is to see how well this treatment works and to understand its safety and impact on quality of life.

Soft Tissue SarcomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

Overactive Bladder in Children: BeDry Study

We are testing solifenacin, mirabegron, and their combination for treating daytime urinary incontinence in children aged 5 to 14. The study aims to see how well these treatments work and their effects on safety and quality of life.

Daytime Urinary Incontinence3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesPediatricsUrology

Acute Agitation: Comparing New Medications

We are studying how well sublingual dexmedetomidine and buccal midazolam work for calming patients in emergency settings compared to oral lorazepam. We also want to know about their safety and how satisfied patients feel with these treatments.

Acute Agitation>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPsychiatry

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology